US20040167208A1 - Use or cyclolignans and new cyclolignans - Google Patents

Use or cyclolignans and new cyclolignans Download PDF

Info

Publication number
US20040167208A1
US20040167208A1 US10/480,800 US48080003A US2004167208A1 US 20040167208 A1 US20040167208 A1 US 20040167208A1 US 48080003 A US48080003 A US 48080003A US 2004167208 A1 US2004167208 A1 US 2004167208A1
Authority
US
United States
Prior art keywords
och
compound
different
igf
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/480,800
Other languages
English (en)
Inventor
Olle Larsson
Magnus Axelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axelar AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to AXELAR AB reassignment AXELAR AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LARSSON, OLLE, AXELSON, MAGNUS
Publication of US20040167208A1 publication Critical patent/US20040167208A1/en
Assigned to BIOVITRUM AB reassignment BIOVITRUM AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AXELAR AB
Priority to US11/346,294 priority Critical patent/US7709526B2/en
Assigned to AXELAR AB reassignment AXELAR AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOVITRUM AB
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings

Definitions

  • the present invention refers to new compounds as well as to the use of new and known compounds inhibiting the insulin-like growth factor-1 receptor, the IGF-1R, for treatment of IGF-1R dependent diseases, especially cancer.
  • the insulin-like growth factor-1 receptor plays an important role in proliferation, protection against apoptosis and transformation of malignant cells.
  • the IGF-1R is also important for maintaining the malignant phenotype of tumour cells, and is involved in tumour cells developing resistance to the action of anti-cancer drugs. In contrast, the IGF-1R seems not to be an absolute requirement for normal cell growth.
  • the IGF-1R consists of two identical extracellular alpha-subunits that are responsible for ligand binding, and two identical beta-subunits with a transmembrane domain and an intracellular tyrosine kinase domain.
  • the ligand-receptor interaction results in phosphorylation of tyrosine residues in the tyrosine kinase domain, which spans from amino acid 973 to 1229 of the ⁇ -subunit.
  • the major sites for phosphorylation are the clustered tyrosines at position 1131, 1135 and 1136 (LeRoith, D., et al., Endocr Rev 1995 April; 16(2), 143-63).
  • the receptor kinase phosphorylates intracellular proteins, like insulin receptor substrate-1 and Shc, which activate the phosphatidyl inositol-3 kinase and the mitogen-activated protein kinase signalling pathways, respectively.
  • IGF-1R is a target for cancer therapy (Baserga, R., et al., Endocrine vol. 7, no. 1, 99-102, August 1997).
  • One strategy to block IGF-1R activity is to induce selective inhibition of the IGF-1R tyrosine kinase.
  • IGF-1R tyrosine kinase
  • tyrphostins A number of synthetic tyrosine kinase inhibitors, called tyrphostins, have been studied by Parrizas, M., et al., Endocrinology 1997, Vol. 138, No. 4, 1427-1433.
  • the IGF-1R is a member of the tyrosine kinase receptor family, which also includes the receptors of insulin, epidermal growth factor (EGF), nerve growth factor (NGF), and platelet-derived growth factor (PDGF). All of the tyrphostins active on IGF-1R cross-react with the insulin receptor, since they are highly homologous, although two of the tyrphostins showed a moderate preference for IGF-1R. It was therefore suggested that it could be possible to design and synthesize small molecules capable of discriminating between these two receptors.
  • Substrate competitive inhibitors of IGF-1 receptor kinase are discussed by Blum, G., et al. in Biochemistry 2000, 39, 15705-15712. A number of lead compounds for inhibitors of the isolated IGF-1R kinase are reported. The search for these compounds was aided by the knowledge of the three-dimensional structure of the insulin receptor kinase domain, which is 84% homologous to the IGF-1R kinase domain. The most potent inhibitor found was tyrphostin AG 538, with an IC50 of 400 nM. However, said inhibitor also blocked the insulin receptor kinase.
  • TAM cytotoxic effect of tamoxifen
  • podophyllotoxin derivatives for which LD50 in rats was high, such as acetylpodophyllotoxin (185 mg/kg) and epipodophyllotoxin (>200 mg/kg) have been considered to essentially lack biological activity (Seidlova-Masinova V., et al. J Nat Cancer Inst, 18, 359-371, 1957).
  • the object of the invention is to find new compounds and new methods for treatment of IGF-1R dependent diseases, especially cancer, by means of an inhibition of the insulin-like growth factor-1 receptor.
  • FIG. 1 shows a computer model of the 12 amino acid peptide comprising the tyrosines 1131, 1135 an 1136 of the IGF-1 receptor.
  • FIG. 2A shows the structural formulas of the compounds podophyllotoxin, deoxypodophyllotoxin, and FIG. 2B shows the structural formulas of epipodophyllotoxin and acetylpodophyllo-toxin.
  • FIG. 1 The three-dimensional structure of short peptides having the amino acid sequence of the IGF-1R tyrosine domain, including the tyrosine residues at position 1131, 1135 an 1136, were analysed using a computer programme in order to find compounds having the ability to mimick the tyrosine residues and interfere with their phosphorylation. It was then discovered when using a 12-amino acid peptide that two of the three key tyrosines, that is 1135 and 1136, which have to be autophosphorylated in IGF-1R for activation, could be situated as close as 0.95 nm (9.5 ⁇ ) from each other, and that the apparent angle between these groups was about 60°. The configuration of said sequence is shown in FIG. 1. Such a short distance has not been observed for the corresponding tyrosines in the insulin receptor.
  • FIG. 1 also depicts the space structures of podophyllotoxin and deoxypodophyllotoxin.
  • the substituents of the inhibitors corresponding to the hydroxy groups in the tyrosines were selected to be methoxy or methylenedioxy groups, since they are chemically relatively stable, i.e. they are not oxidized or phosphorylated.
  • the distance between these substituents should be about 0.95 ⁇ 0.10 nm (9.5 ⁇ 1.0 ⁇ ).
  • an inhibitory molecule In order to penetrate the receptor, an inhibitory molecule has to be small.
  • podophyllotoxin When for instance podophyllotoxin was conjugated with a glucoside derivative, podophyllotoxin-4,6-O-benzylidene- ⁇ -D-glucopyranoside, the effect on IGF-1R completely disappeared.
  • the size of the molecule increased due to the reduced substituents sticking out from the molecule, resulting in a dramatically reduced activity of the compounds.
  • Increasing the size by forming methylenedioxy derivatives or acetonides of podophyllotoxindiol also resulted in compounds with little or no activity.
  • the inhibitor molecule also has to be relatively nonpolar, so that it can freely penetrate cell membranes and the IGF-1 receptor, but sufficiently polar to be reasonably soluble in water.
  • the polarity of the molecule is determined by the number and nature of the oxygen functions. The polarity seems to be optimal when the water solubility is between that of deoxypodophyllotoxin, i.e. about 0.01 mM, and that of podophyllotoxin, about 0.1-0.2 mM. No charged or highly polar groups should be present on the molecule.
  • the invention refers to the use of a compound comprising the formula
  • R is OH, OCH 3 , OC 2 H 5 or a C1-5 linear or branched hydrocarbon chain, optionally having 1-3 oxygen functions, and optionally forming a bond with the carbon (number 5) in the top benzene ring.
  • R 1 which can be the same or different, is OH or OCH 3 , and n is 0-2;
  • Oxygen functions in this context refer to hydroxy, oxo, carboxy, methoxy, methylenedioxy, lactone, ether and/or ester groups.
  • R is OH, OCH 3 , OC 2 H 5 ,CH 3 , C 2 H 5 , or C 2 H 4 OH; and R 1 and n are as defined above.
  • the substituent R of the compounds of this group can be in the R or S position in relation to the bottom benzene ring.
  • R 2 , R 3 and R 4 which can be the same or different, are H, OH, O, OCH 3 , OC 2 H 5 or R 2 and R 3 together is a methylenedioxy group, or R 3 and R 4 together is an acetonide, carbonate or methylendioxy group; and R 1 and n are as defined above.
  • the substituents R 2 , R 3 and R 4 can, when not expressing an oxo group, be in either alpha- or beta-position.
  • the bottom benzene ring should preferably be in the alpha-position.
  • NBS is N-bromosuccinimide
  • PPA is polyphosphoric acid
  • TTN is thalliumnitrate trihydrate
  • p-TSA is p-toluene sulfonic acid
  • DMF is N,N-dimethylformamide
  • LDA lithium dialkylamide
  • Still another group of compounds which can be used in accordance with the invention are compounds of the formula III
  • R 2 , R 5 , R 6 which can be the same or different, are H, OH, OOCH 3 , OOCH 2 CH 3 , OCH 3 , or OC 2 H 5 , or R 5 and R 6 together is an ether or a lactone; and R 1 and n are as defined above.
  • the substituent R 2 when being a free hydroxy group cannot be in the alpha-position, as in podophyllotoxin.
  • Other R 2 substituents, except an oxo group can be in either alpha- or beta-position.
  • the bottom benzene ring is in the alpha-position and there is a beta-bond between the carbons numbered 8 and 9 and an alpha-bond between the carbons numbered 8′ and 9′, thus they form a trans configuration, as in for example deoxypodophyllotoxin and podophyllotoxin.
  • the invention especially refers to the use of any of the relatively non-toxic cyclolignans, such as epipodophyllotoxin, deoxypodophyllotoxin and acetylpodophyllotoxin, as an inhibitor of tyrosine autophosphorylation of the insulin-like growth factor-1 receptor, whereas the use of more cytotoxic and tissue irritating compounds, such as podophyllotoxin and 4′-demethyl-podophyllotoxin, should be avoided.
  • any of the relatively non-toxic cyclolignans such as epipodophyllotoxin, deoxypodophyllotoxin and acetylpodophyllotoxin
  • Some compounds of the formula III are naturally occurring in plants, such as deoxypodophyllotoxin and podophyllotoxin.
  • deoxypodophyllotoxin and podophyllotoxin For the preparation of said substances in pure form, dried and finely ground rhizomes of e.g. Podophyllum emodi or Podophyllum peltatum are extracted with organic solvents. The extract is then filtered and concentrated on silica gel. The fractions containing the substances are collected and the latter are further purified by chromatography on acid alumina and silica gel etc., and finally recrystallized.Podophyllotoxin may be used as the starting material for the syntheses of its less toxic derivatives.
  • Epipodophyllotoxin is readily prepared from podophyllotoxin. Five mg of the latter are dissoved in 2.5 mL of acetone. To the solution is added 0,5 mL of concentrated HCl, and the mixture is boiled for 2 hours. The solution is then neutralized with aqueous NaHCO3 (about 0.5 g in 5 mL) and following evaporation of the acetone, the product epipodophyllotoxin is extracted with ethyl acetate.
  • Acetylpodophyllotoxine (the acetate derivative of podophyllotoxin) can be prepared from podophyllotoxin by incubating 0.1 mg of the latter with 1 mL of acetic anhydride and 1 mL of pyridine at 50° C. for 16 hours. The reagents are then partly evaporated, 10 mL of water and 10 mL of ethyl acetate are added and the product is then extracted from the aqueous phase.
  • Acetonides and methylenedioxy derivatives can be prepared starting from diols obtained by reducing the lactone ring of natural lignans according to standard procedures.
  • R is OH, OCH 3 , OC 2 H 5 , CH 3 , C 2 H 5 , or C 2 H 4 OH; and R 1 and n are as defined above, with the proviso that when R 1 is OCH 3 and n is 2, R is not OH, that when R is a CH 3 or C 2 H 5 , R 1 is OH and n is 1 or 2, that when R is C 2 H 5 , R 1 is not OH.
  • the molecule of the invention should be relatively rigid, in order to keep the distance between the two substituents within the given range, that is 0.95 ⁇ 0.10 nm (9.5 ⁇ 1.0 ⁇ ). Forming a ring structure of the hydrocarbon chain will prevent rotation or motion of the benzene ring, and so does lactone formation.
  • R 2 , R 3 and R 4 which can be the same or different, are H, OH, O, OCH 3 , or R 2 and R 3 together is a methylenedioxy group, or R 3 and R 4 together is an acetonide, carbonate or methylendioxy group; and R 1 and n are as defined above.
  • Podophyllotoxin has for long been implicated in cancer therapy, but in the way it was administered to patients it produced unacceptable side effects.
  • a 100-fold lower concentrations were sufficient to inactivate the IGF-1R.
  • podophyllotoxin and analogues do not inhibit the insulin receptor, which is highly homologous to IGF-1R. Moreover, they do not inhibit other major growth factor receptor kinases either.
  • Relatively nontoxic compounds of the formula I can be used for treatment of IGF-1R dependent diseases, such as cancer, arteriosclerosis, including prevention of restenosis of the coronary arteries after vascular surgery, psoriasis and acromegaly.
  • a pharmaceutical composition comprising a compound of the formula I in combination with a physiologically acceptable carrier and optional additives can be administered to a patient by any suitable route, such as parenterally, preferably by intravenous infusion, or topically, for instance by a patch.
  • the invention refers to the new compounds of the formula I or II for use as a medicament, and especially for the preparation of a medicament for treatment of cancer.
  • the invention consequently also refers to a method of treatment of a cancer in a mammal, comprising the steps of administrating a pharmaceutical composition, containing a compound having the formula I in combination with a physiologically acceptable carrier, by constant infusion to a patient suffering from a tumour, controlling the plasma level of the compound, and adjusting the rate of infusion to keep the plasma level between 0.05 and 5.0 ⁇ M (depending on the general toxicity of the copound), for a period of time being sufficient for the tumour to be retarded or to disappear.
  • the compounds of the invention can be useful to sensitise the tumour cells to the effects of other anti-cancer drugs.
  • Cell culture reagents that is media, fetal calf serum and antibiotics, were purchased from Gibco, Sweden. All other chemicals unless stated otherwise were from Sigma (St. Louis. Mo., USA).
  • a mouse monoclonal antibody against phosphotyrosine (PY99) and a polyclonal antibody against ⁇ -subunit of IGF-1R (N20) were obtained from Santa Cruz Biotechnology Inc (Santa Cruz, Calif., USA).
  • a monoclonal antibody against the ⁇ -subunit of IGF-1R (IR-3) was purchased from Oncogene Science (N.Y., USA).
  • Deoxypodophyllotoxin and podophyllotoxin 99.97% purity
  • acetylpodophyllotoxin, podophyllotoxone and 4′-demethylpodophyllotoxin >95% purity
  • the human malignant melanoma cell lines SK-MEL-2, SK-MEL-5 and SK-MEL-28, the prostatic carcinoma cell line PC-3, and the breast cancer cell line MCF-7 were from the American Tissue Culture Collection, USA.
  • the malignant melanoma cell lines BE, and FM55 were obtained from Professor R Kiessling, CCK, Karolinska Hospital, Sweden.
  • the R- and P6 cell lines were gifts from Professor R. Baserga, Thomas Jefferson University, Philadelphia, Pa., USA. All cell lines were cultured in Minimal Essential Medium containing 10% faetal bovine serum, glutamine, 1% benzylpenicillin and streptomycin.
  • the cells were grown in monolayers in tissue culture flasks maintained at 95% air/5% CO 2 atmosphere at 37° C. in a humidified incubator.
  • cells were cultured in either 35-mm or 60-mm plastic dishes or 96-well plastic plates. The experiments were initiated under subconfluent growth conditions.
  • the human chronic myeloid leukemia K562/S and K562/Vcr30 lines and the acute myeloid leukemia cell lines HL60/0 and HL60/Nov were obtained from ATCC.
  • the K562/S and HL60/0 are wild type (non-resistant) cells, whereas K562/Vcr30 and HL60/Nov are cytostatic-resistant sublines.
  • All leukemia cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and with 2 mM glutamine, 1% benzyl-penicillin and streptomycin.
  • the cells were grown in tissue culture flasks maintained at 95% air/5% CO 2 atmosphere at 37° C. in a humidified incubator. For the experiments 25,000 cells were cultured in 60-mm plastic dishes or 96-well plastic plates.
  • the experiments on leukemia cells were performed in collaboration with Associate professor NASAd Vitols, Department of Pharmacology, Karolinska Hospital (Stockholm, Sweden).
  • Cell proliferation kit II (Roche Inc.) is based on colorimetric change of the yellow tetrazolium salt XTT in orange formazan dye by the respiratory chain of viable cells (Roehm, N W, et al., J Immunol Methods 142:257-265, 1991).
  • Cells seeded at a concentration of 5000/well in 100 ⁇ l medium in a 96-well plate were treated with different drugs in the given concentration. After 24 or 48 h the cells were incubated, according to the manufacturer 's protocol, with XTT labelling mixture. After 4 h the formazan dye is quantified using a scanning multiwell spectrophotometer with a 495-nm filter. The absorbance is directly correlated with number of viable cells. The standard absorbance curve was drawn by means of untreated cells seeded at a concentration of from 1000 to 10 000 cells/well with an increasing rate of 1000 cells/well. All standards and experiments were performed in triplicates.
  • the isolated cells were lyzed in 10 ml ice-cold PBSTDS containing protease inhibitors (Carlberg, M., et al., J Biol Chem 271:17453-17462, 1996). 50 ⁇ l protein A or G agarose was added in 1 ml sample and incubated for 15 min at 4° C. on an orbital shaker. After centrifugation for 10 min at 10,000 r/min at 4° C. the supernatant was saved. The protein content was determined by a dye-binding assay with a reagent purchased from Bio-Rad. Bovine serum albumin was used as a standard.
  • Protein samples were solved in a 2 ⁇ -sample buffer containing Laemmli buffer and 0.5% methanol and boiled for 5 min at 96° C. Samples were separated by SDS-PAGE with a 4% stacking gel and 7.5% separation gel. Molecular weight markers (Bio Rad, Sweden) were run simultaneously in all experiments.
  • IGF-1R tyrosine autophosphorylation was analysed by a sandwich ELISA assay. Briefly, 96-well plates (Immunolon, Nunc) were coated overnight at 4° C. with 1 ⁇ g/well of the monoclonal antibody Ab-5 (LabVision) to the IGF-1R beta subunit. The plates were blocked with 1% BSA in PBS Tween for 1 h, then 80 g/well of total protein lysate from the P6 cell line was added. As a negative control was used total protein lysate from R-cell line. The investigated compounds were added in tyrosine kinase buffer without ATP at room temperature for 30 min, prior to kinase activation with ATP. Kinase assay was performed using the Sigma kit. After spectrophotometry the IC50 values of inhibitors were determined using the Regression function of Statistica program.
  • FM 55 melanoma cells were cultured in the same way as described in Experiment 1. When reaching a density of 65,000 cells/cm 2 in the dishes, they were treated for 1 h with 0.05 ⁇ M podophyllotoxin, deoxypodophyllotoxin, acetylpodophyllotoxin, epipodophyllotoxin, 4′-demethyl-podophyllotoxin and podophyllotoxone. The cells were then harvested for assay and quantification of IGF-1R autophosphorylation as described above. The values shown in Table 2 represent means of 3 experiments.
  • FM55 melanoma cells were cultured in the same way as described in Experiment 3 and were treated with different doses of podophyllotoxin analogues as described in Experiment 3. The results (IC50 values) are given in the following Table 4. TABLE 4 IC50 ( ⁇ M) for viability of FM55 cells Compound IC50 Podophyllotoxin 0.05 Deoxypodophyllotoxin 0.04 Acetylpodophyllotoxin 0.03 4′-demethylpodophyllotoxin 0.04
  • the leukemia cell lines K562/S, K562/Vcr 30, HL60/0 and HL60/Nov were proven to express the IGF-1R.This was assayed by Western blotting analysis, as described in Methods and Experiment 1 and 2.
  • the 4 leukemia cell lines were seeded in 96-well plates (medium volume in a well was 100 ⁇ l), in RPMI40 medium supplemented with fetal calf serum. After 24 h podophyllotoxin, deoxypodophyllotoxin and other derivatives were added at different concentrations for 72 h. Cell viability was then assayed (see above). IC50 values for each inhibitor and cell lines are shown below (Table 5).
  • Podophyllotoxin-induced inactivation of the insulin-like growth factor-1 receptor caused extensive cell death in malignant cells, whereas cells devoid of insulin-like growth factor-1 receptors were resistant.
  • the non-toxic derivative picropodophyllin was equipotent to podophyllotoxin in inhibiting the insulin-like growth factor-1 receptor activity and inducing cell death. This new mechanism of podophyllotoxin and derivatives may be useful in therapy of cancer and other IGF-1R dependent diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US10/480,800 2001-06-19 2002-06-19 Use or cyclolignans and new cyclolignans Abandoned US20040167208A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/346,294 US7709526B2 (en) 2001-06-19 2006-02-03 Use of cyclolignans and new cyclolignans

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102168A SE0102168D0 (sv) 2001-06-19 2001-06-19 New use and new compounds
SE0102168-2 2001-06-19
PCT/SE2002/001223 WO2002102805A1 (fr) 2001-06-19 2002-06-19 Nouvelle utilisation de cyclolignans et nouveaux cyclolignans

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/346,294 Division US7709526B2 (en) 2001-06-19 2006-02-03 Use of cyclolignans and new cyclolignans

Publications (1)

Publication Number Publication Date
US20040167208A1 true US20040167208A1 (en) 2004-08-26

Family

ID=20284528

Family Applications (7)

Application Number Title Priority Date Filing Date
US10/480,800 Abandoned US20040167208A1 (en) 2001-06-19 2002-06-19 Use or cyclolignans and new cyclolignans
US10/481,441 Expired - Fee Related US7348358B2 (en) 2001-06-19 2002-06-19 Use of cyclolignans
US11/346,294 Expired - Fee Related US7709526B2 (en) 2001-06-19 2006-02-03 Use of cyclolignans and new cyclolignans
US12/021,578 Expired - Fee Related US7662851B2 (en) 2001-06-19 2008-01-29 Use of specific cyklolignans
US12/021,530 Expired - Fee Related US7629381B2 (en) 2001-06-19 2008-01-29 Use of specific cyklolignans
US12/508,218 Expired - Fee Related US8389747B2 (en) 2001-06-19 2009-07-23 Use of specific cyklolignans
US12/714,107 Abandoned US20100216728A1 (en) 2001-06-19 2010-02-26 New use of specific cyklolignans

Family Applications After (6)

Application Number Title Priority Date Filing Date
US10/481,441 Expired - Fee Related US7348358B2 (en) 2001-06-19 2002-06-19 Use of cyclolignans
US11/346,294 Expired - Fee Related US7709526B2 (en) 2001-06-19 2006-02-03 Use of cyclolignans and new cyclolignans
US12/021,578 Expired - Fee Related US7662851B2 (en) 2001-06-19 2008-01-29 Use of specific cyklolignans
US12/021,530 Expired - Fee Related US7629381B2 (en) 2001-06-19 2008-01-29 Use of specific cyklolignans
US12/508,218 Expired - Fee Related US8389747B2 (en) 2001-06-19 2009-07-23 Use of specific cyklolignans
US12/714,107 Abandoned US20100216728A1 (en) 2001-06-19 2010-02-26 New use of specific cyklolignans

Country Status (15)

Country Link
US (7) US20040167208A1 (fr)
EP (5) EP1938818A3 (fr)
JP (2) JP2004534078A (fr)
KR (1) KR100940055B1 (fr)
CN (3) CN1659171A (fr)
AT (1) ATE441411T1 (fr)
AU (2) AU2002311731B8 (fr)
CA (2) CA2455328C (fr)
DK (1) DK1498121T3 (fr)
ES (1) ES2333014T3 (fr)
NO (1) NO332642B1 (fr)
NZ (2) NZ530290A (fr)
PT (1) PT1498121E (fr)
SE (1) SE0102168D0 (fr)
WO (2) WO2002102804A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154982A1 (en) * 2001-06-19 2006-07-13 Axelar Ab Use of cyklolignans and new cyklolignans
US20090271879A1 (en) * 2008-02-09 2009-10-29 Berkowitz David B Analogues of (-)-picropodophyllin, synthesis and uses thereof
US20150231111A1 (en) * 2013-05-10 2015-08-20 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
SE0203747D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New use
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
AU2004282219C1 (en) 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
US7781393B2 (en) 2004-02-25 2010-08-24 Dana-Farber Cancer Institute, Inc. Methods for inhibiting tumor cell growth
CN100590118C (zh) 2004-03-12 2010-02-17 阿纳里特康股份有限公司 作为类胰岛素生长因子第1类受体抑制剂的杂环化合物
PT1740591E (pt) * 2004-04-02 2009-09-24 Osi Pharm Inc Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
EP1926996B1 (fr) 2005-09-20 2011-11-09 OSI Pharmaceuticals, Inc. Marqueurs biologiques prédictifs d'une réaction anticancéreuse aux inhibiteurs kinase du récepteur du facteur de croissance 1 analogue à l'insuline
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
CA2638124A1 (fr) * 2006-02-24 2007-08-30 Axelar Ab Utilisation de cyclolignans dans le traitement du diabete de type 2 et comme contraceptifs
EP2056808A4 (fr) * 2006-08-28 2009-12-23 Univ California Potentialisateur de petite molécule utilisé en hormonothérapie pour le cancer du sein
EP2250173A1 (fr) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Dérivés d'imidazopyrazinol pour le traitement des cancers
WO2009108857A2 (fr) * 2008-02-27 2009-09-03 Combithera, Inc. Thérapie de combinaison pour le cancer de la prostate
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
EP2283020B8 (fr) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Imidazopyrazines et imidazotriazines substituées
MX2011004824A (es) 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
WO2010129740A1 (fr) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Utilisation d'osi-906 dans le traitement du carcinome adrénocortical
WO2010138686A1 (fr) * 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents s'opposant au gène mdr1
US7924203B2 (en) * 2009-06-12 2011-04-12 Analog Devices, Inc. Most significant bits analog to digital converter, and an analog to digital converter including a most significant bits analog to digital converter
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
EP2542893A2 (fr) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
CA2783656A1 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques predictifs d'une reponse anticancereuse aux inhibiteurs de kinase du recepteur du facteur de croissance insulinique 1
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
PL2611811T3 (pl) 2010-08-31 2017-07-31 Axelar Ab Nowy sposób wytwarzania cyklolignanów
RU2013120990A (ru) 2010-10-08 2014-11-20 Акселар Аб Полиморфы в или с пикроподофиллина для использования в противораковой терапии
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
JP5892508B2 (ja) * 2011-05-23 2016-03-23 国立大学法人 鹿児島大学 抗腫瘍剤及びその製造方法
WO2013124382A1 (fr) * 2012-02-24 2013-08-29 Nestec S.A. Peltatine destinée à être utilisée pour traiter des troubles cardiovasculaires
WO2013132262A1 (fr) 2012-03-09 2013-09-12 Axelar Ab Dérivés de picropodophylline
WO2013132263A1 (fr) 2012-03-09 2013-09-12 Axelar Ab Dérivés de picropodophylline pour utilisation en thérapie
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
WO2014102889A1 (fr) * 2012-12-25 2014-07-03 国立大学法人鹿児島大学 Agent antitumoral et son procédé de production
CA2941010A1 (fr) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancerotherapie
CA2923667A1 (fr) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Traitement du cancer
CN104434909A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途
WO2015168255A1 (fr) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Procédés et compositions de ciblage de cellules souches cancéreuses
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
JP6550538B2 (ja) 2015-10-27 2019-07-24 カリフォルニア パシフィック メディカル センター ポドフィロトキシン誘導体およびそれらの使用
CN110669054B (zh) * 2018-07-03 2022-04-26 南京药石科技股份有限公司 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途
KR102378151B1 (ko) * 2020-05-11 2022-03-24 주식회사 제이앤씨사이언스 베타-아포피크로포도필린의 신규한 유도체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825730A (en) * 1953-02-04 1958-03-04 Thompson Boyce Plant Res Organic compounds
US4342777A (en) * 1979-03-29 1982-08-03 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584370D1 (de) 1984-12-28 1991-11-14 Conpharm Ab Verwendung von podophyllotoxin und dessen derivaten.
NO170760C (no) 1985-01-10 1992-12-02 Tanabe Seiyaku Co Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
SE468213B (sv) * 1986-06-27 1992-11-23 Conpharm Ab Anvaendning av podophyllotoxin eller ett derivat daerav till framstaellning av en farmakologisk beredning foer behandling av kollagenoser, saerskilt reumatoid artrit
WO1988003800A1 (fr) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Inhibiteurs de lipoxygenase
SE464167B (sv) * 1989-07-31 1991-03-18 Analytecon Sa Topisk farmaceutisk beredning av podophyllotoxin
CN1075316A (zh) 1992-10-22 1993-08-18 布里斯托尔-米尔斯·斯奎布公司 表鬼臼毒中间体的制备方法
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
JPH09194368A (ja) * 1996-01-11 1997-07-29 Pola Chem Ind Inc ポドフィロトキシン誘導体及びそれからなる新規細胞分化誘導剤
US5726027A (en) 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
DE69834828T2 (de) * 1997-11-27 2007-01-04 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
WO2000000238A1 (fr) 1998-06-26 2000-01-06 Quanam Medical Corporation Inhibiteurs de topoisomerase permettant de prevenir la restenose
AU2001225432A1 (en) 2000-01-20 2001-07-31 Supratek Pharma, Inc. Novel podophyllotoxin compositions
JP4024148B2 (ja) * 2000-11-20 2007-12-19 ソンベ キム 新規な４’−デメチル−４’−ｏ−置換−１−デオキシポドフィロトキシン誘導体及びその幾何異性体、その製造方法及びそれを含んでなる抗癌剤組成物
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
EP2260846B1 (fr) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Nouveaux procédés pour le traitement du cancer
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825730A (en) * 1953-02-04 1958-03-04 Thompson Boyce Plant Res Organic compounds
US4342777A (en) * 1979-03-29 1982-08-03 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154982A1 (en) * 2001-06-19 2006-07-13 Axelar Ab Use of cyklolignans and new cyklolignans
US7709526B2 (en) 2001-06-19 2010-05-04 Biovitrum Ab Use of cyclolignans and new cyclolignans
US20090271879A1 (en) * 2008-02-09 2009-10-29 Berkowitz David B Analogues of (-)-picropodophyllin, synthesis and uses thereof
US8859614B2 (en) 2008-02-09 2014-10-14 University of Nebraska—Lincoln Analogues of (−)-picropodophyllin, synthesis and uses thereof
US20150231111A1 (en) * 2013-05-10 2015-08-20 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds
US9833434B2 (en) * 2013-05-10 2017-12-05 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds
US9907783B2 (en) 2013-05-10 2018-03-06 m.Alphabet 2, LLC Methods of treating skin conditions using cyclolignan compounds

Also Published As

Publication number Publication date
JP5071910B2 (ja) 2012-11-14
CN100503611C (zh) 2009-06-24
CA2451047C (fr) 2012-10-09
US7709526B2 (en) 2010-05-04
JP2005500300A (ja) 2005-01-06
US20090326248A1 (en) 2009-12-31
US8389747B2 (en) 2013-03-05
CN1659171A (zh) 2005-08-24
AU2002314671B2 (en) 2008-09-18
PT1498121E (pt) 2009-12-04
US7348358B2 (en) 2008-03-25
JP2004534078A (ja) 2004-11-11
NZ530290A (en) 2005-05-27
NZ530172A (en) 2004-12-24
US20060154982A1 (en) 2006-07-13
US20100216728A1 (en) 2010-08-26
WO2002102804A1 (fr) 2002-12-27
NO20035648L (no) 2004-02-18
EP1498121B1 (fr) 2009-09-02
WO2002102805A1 (fr) 2002-12-27
AU2002311731C1 (en) 2009-09-03
KR20040007743A (ko) 2004-01-24
WO2002102804A8 (fr) 2004-05-13
CA2455328A1 (fr) 2002-12-27
CA2455328C (fr) 2011-09-20
KR100940055B1 (ko) 2010-02-04
DK1498121T3 (da) 2009-12-14
AU2002311731B2 (en) 2009-02-26
EP1938819A2 (fr) 2008-07-02
US20080119528A1 (en) 2008-05-22
US7662851B2 (en) 2010-02-16
EP1498121A1 (fr) 2005-01-19
EP1938818A3 (fr) 2010-04-07
ATE441411T1 (de) 2009-09-15
NO20035648D0 (no) 2003-12-17
US7629381B2 (en) 2009-12-08
SE0102168D0 (sv) 2001-06-19
US20040186169A1 (en) 2004-09-23
CA2451047A1 (fr) 2002-12-27
CN1543466A (zh) 2004-11-03
ES2333014T3 (es) 2010-02-16
CN101606929A (zh) 2009-12-23
EP1938819A3 (fr) 2010-04-07
NO332642B1 (no) 2012-11-26
EP1938818A2 (fr) 2008-07-02
EP2186513A1 (fr) 2010-05-19
AU2002311731B8 (en) 2009-10-29
US20080221207A1 (en) 2008-09-11
EP1397369A1 (fr) 2004-03-17

Similar Documents

Publication Publication Date Title
US7709526B2 (en) Use of cyclolignans and new cyclolignans
AU2002314671A1 (en) New use of cyclolignans and new cyclolignans
AU2002311731A1 (en) New use of specific cyclolignans
Mereyala et al. Cytotoxic activity of styryl lactones and their derivatives
US20070123491A1 (en) Podophyllotoxin derivatives as igf-1r inhibitors
AU2009201542B2 (en) New use of specific cyclolignans
EP1397368A1 (fr) Nouvelle utilisation de cyclolignans specifiques

Legal Events

Date Code Title Description
AS Assignment

Owner name: AXELAR AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LARSSON, OLLE;AXELSON, MAGNUS;REEL/FRAME:015173/0107;SIGNING DATES FROM 20031111 TO 20031114

AS Assignment

Owner name: BIOVITRUM AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AXELAR AB;REEL/FRAME:015391/0453

Effective date: 20041112

AS Assignment

Owner name: AXELAR AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVITRUM AB;REEL/FRAME:017246/0026

Effective date: 20060207

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION